Investigating outcomes associated with medication use during pregnancy: A review of methodological challenges and observational study designs

Reproductive Toxicology

Volumn 33, Issue 3, 2012, Pages 280-289

  Grzeskowiak, Luke E ^a   Gilbert, Andrew L ^a   Morrison, Janna L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Bias; Epidemiology; Human; Observational studies; Pregnancy; Pregnancy outcome

Indexed keywords

FOLIC ACID; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; UTERUS SPASMOLYTIC AGENT; VALPROIC ACID;

BRAIN DEVELOPMENT; COHORT ANALYSIS; DOSE RESPONSE; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; ENVIRONMENTAL EXPOSURE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; INCIDENCE; INTRAUTERINE GROWTH RETARDATION; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; REVIEW; TERATOGENICITY; VALIDITY;

BIAS (EPIDEMIOLOGY); DATA INTERPRETATION, STATISTICAL; DRUG THERAPY; FEMALE; HUMANS; PREGNANCY; RESEARCH DESIGN;

EID: 84859754300     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2012.01.006     Document Type: Review

References (68)

1. Mitchell A. Systematic identification of drugs that cause birth defects - a new opportunity [editorial]. N Engl J Med 2003, 349:2556-2559.
2. Irl C., Hasford J. Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf 2000, 22:169-177.
3. Höfler M. The Bradford Hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol 2005, 2:11.
4. Mitchell A. Special considerations in studies of drug-induced birth defects. Pharmacoepidemiology 2000, 749-763. John Wiley & Sons, Ltd., England. third ed. B.L. Strom (Ed.).
5. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P., et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007, 4:1623-1627.
6. Strom B.L. Pharmacoepidemiology 2000, John Wiley & Sons, Ltd., England. third ed.
7. Lu C.Y. Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract 2009, 63:691-697.
8. Alwan S., Friedman J.M. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009, 23:493-509.
9. Schaefer C., Ornoy A., Clementi M., Meister R., Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod Toxicol 2008, 26:36-41.
10. Bar-Oz B., Moretti M.E., Mareels G., Van Tittelboom T., Koren G. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet 1999, 354:1700-1701.
11. Gray R.H., Becker S. Selected topics in the epidemiology of reproductive outcomes. Epidemiol Rev 2000, 22:71-75.
12. Pedersen L.H., Henriksen T.B., Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010, 125:e600-e608.
13. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., Friedman J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007, 356:2684-2692.
14. Louik C., Lin A.E., Werler M.M., Hernandez-Diaz S., Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007, 356:2675-2683.
15. Bakker M.K., Kerstjens-Frederikse W.S., Buys C., de Walle H.E.K. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010, 88:94-100.
16. Psaty B.M., Koepsell T.D., Lin D., Pahor M., Furberg C.D. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999, 47:749-754.
17. Bar-Oz B., Einarson T., Einarson A., Boskovic R., O'Brien L., Malm H., et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007, 29:918-926.
18. Brent R.L. Addressing environmentally caused human birth defects. Pediatr Rev 2001, 22:153-165.
19. Czeizel A.E. The estimation of human teratogenic/fetotoxic risk of exposures to drugs on the basis of Hungarian experience: a critical evaluation of clinical and epidemiological models of human teratology. Expert Opin Drug Saf 2009, 8:283-303.
20. Petik D., ács N., Bánhidy F., Czeizel A. A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health 2008, 24:69-78.
21. Czeizel A.E., Puhó E.H., ács N., Bánhidy F. Use of specified critical periods of different congenital abnormalities instead of the first trimester concept. Birth Defects Res A Clin Mol Teratol 2008, 82:139-146.
22. Heikkinen T., Ekblad U., Palo P., Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003, 73:330-337.
23. Grzeskowiak L.E., Gilbert A.L., Morrison J.L. Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy. Eur J Clin Pharmacol 2011, doi:10.1007/s00228-011-1154-9.
24. Vajda F.J., O'Brien T.J., Hitchcock A., Graham J., Cook M., Lander C., et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004, 11:854-858.
25. Diav-Citrin O., Shechtman S., Bar-Oz B., Cantrell D., Arnon J., Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 2008, 22:325-334.
26. Kaneko S., Battino D., Andermann E., Wada K., Kan R., Takeda A., et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999, 33:145-158.
27. Berard A., Ramos E., Rey E., Blais L., St-Andre M., Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007, 80:18-27.
28. Diav-Citrin O., Shechtman S., Weinbaum D., Wajnberg R., Avgil M., Di Gianantonio E., et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008, 66:695-705.
29. Oberlander T.F., Warburton W., Misri S., Riggs W., Aghajanian J., Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008, 83:68-76.
30. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008, 192:338-343.
31. Savitz D.A., Dole N., Herring A.H. Methodologic issues in the design and analysis of epidemiologic studies of pregnancy outcome. Stat Methods Med Res 2006, 15:93-102.
32. Olsen J., Czeizel A., Sørensen H.T., Nielsen G.L., Irgens L.M., Olesen C., et al. How do we best detect toxic effects of drugs taken during pregnancy?: A EuroMap paper. Drug Saf 2002, 25:21-32.
33. Källén B.A.J. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto) 2005, 45:44-51.
34. Koren G. The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol 2011, 18:e174-e175.
35. Espnes M.G., Bjørge T., Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011, 20:243-248.
36. Stephansson O., Granath F., Svensson T. Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol 2011, 3:43-50.
37. Mamdani M., Sykora K., Li P., Normand S.L.T., Streiner D.L., Austin P.C., et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005, 330:960-962.
38. Haas D.M., Imperiale T.F., Kirkpatrick P.R., Klein R.W., Zollinger T.W., Golichowski A.M. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009, 113:585-594.
39. Green N.S. Folic acid supplementation and prevention of birth defects. J Nutr 2002, 132:2356S-2360S.
40. Van Beynum I.M., Kapusta L., Bakker M.K., Den Heijer M., Blom H.J., de Walle H.E.K. Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: a registry-based case-control study in the northern Netherlands. Eur Heart J 2010, 31:464-471.
41. Hernández-Díaz S., Werler M.M., Walker A.M., Mitchell A.A. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000, 343:1608-1614.
42. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354:579-587.
43. Wooltorton E. Persistent pulmonary hypertension of the newborn and maternal use of SSRIs. CMAJ 2006, 174:1555-1556.
44. Louis G.B., Dukic V., Heagerty P.J., Louis T.A., Lynch C.D., Ryan L.M., et al. Analysis of repeated pregnancy outcomes. Stat Methods Med Res 2006, 15:103-126.
45. Andrade S.E., McPhillips H., Loren D., Raebel M.A., Lane K., Livingston J., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009, 18:246-252.
46. Shakir S.A.W., Layton D. Causal Association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 2002, 25:467.
47. Sannerstedt R., Lundborg P., Danielsson B.R., Kihlströ.M I., Alvan G., Prame B., et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996, 14:69-77.
48. Koren G., Pastuszak A., Ito S. Drugs in pregnancy. N Engl J Med 1998, 338:1128-1137.
49. Schardein J.L. Chemically induced birth defects 2000, Marcel Dekker, Inc., New York. third ed.
50. Kim E., Sarkar M., Navioz Y., Koren G., Einarson A. The motherisk alcohol and substance use helpline: 10 years of experience and counting. J Popul Ther Clin Pharmacol 2010, 17:e269-e280.
51. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335:1010-1015.
52. Schaefer C., Hannemann D., Meister R., Elefant E., Paulus W., Vial T., et al. Vitamin K antagonists and pregnancy outcome: a multi-centre prospective study. Thromb Haemost 2006, 95:949-957.
53. Einarson A., Pistelli A., DeSantis M., Malm H., Paulus W.D., Panchaud A., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008, 165:749-752.
54. Sivojelezova A., Shuhaiber S., Sarkissian L., Einarson A., Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Ostet Gynecol 2005, 193:2004-2009.
55. Olsen J., Melbye M., Olsen S.F., Sorensen T.I.A., Aaby P., Nybo Andersen A.M., et al. The Danish National Birth Cohort - its background, structure and aim. Scand J Public Health 2001, 29:300-307.
56. Magnus P., Irgens L.M., Haug K., Nystad W., Skjærven R., Stoltenberg C. Cohort profile: the Norwegian mother and child cohort study (MoBa). Int J Epidemiol 2006, 35:1146-1150.
57. Moretti M. Collection and analysis of drug safety data in pregnancy. Can J Clin Pharmacol 2007, 14:e34-e36.
58. Shields K.E., Wiholm B-E., Hostelley L.S., Striano L.F., Arena S.R., Sharrar R.G. Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program. Drug Saf 2004, 27:353-367.
59. Vajda F.J.E., O'Brien T., Hitchcock A., Graham J., Lander C., Eadie M. The Australian antiepileptic drug in pregnancy register: aspects of data collection and analysis. J Clin Neurosci 2007, 14:936-942.
60. Kulkarni J., McCauley-Elsom K., Marston N., Gilbert H., Gurvich C., de Castella A., et al. Preliminary findings from the national register of antipsychotic medication in pregnancy. Australas Psychiatry 2008, 42:38-44.
61. Colvin L., Slack Smith L., Stanley F.J., Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011, 91:142-152.
62. Pedersen L.H., Henriksen T.B., Vestergaard M., Olsen J., Bech B.H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009, 339:b3569.
63. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63:898-906.
64. Cole J.A., Ephross S.A., Cosmatos I.S., Walker A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:1075-1085.
65. Holman C.D.J., Bass J.A., Rouse I.L., Hobbs M.S.T. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999, 23:453-459.
66. Andrews E.B., Tennis P. Promise and pitfalls of administrative data in evaluating pregnancy outcomes. Pharmacoepidemiol Drug Saf 2007, 16:1181-1183.
67. Kulin N.A., Pastuszak A., Sage S.R., Schick-Boschetto B., Spivey G., Feldkamp M., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998, 279:609-610.
68. Etminan M., Pharmacoepidemiology I.I. The nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004, 24:1105-1109.